Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ZKH vs ZJYL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZJYL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

ZJYL Overall Winner 6-Pillar Tally: ZKH 1 – 4 ZJYL (1 Tie) Matrix Metrics: ZKH 4 – 6 ZJYL

As of Nov 19, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over ZKH Group Limited (ZKH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ZKH carries a Unified Composite Score of 50.3/100 (HOLD) at $1.47 (3.3x Forward P/E, -0.8% operating margin), whereas ZJYL carries 33.4/100 (SELL) at $3.34 (N/M Forward P/E, 2.1% operating margin).

  • Composite vs. Pillar Nuance: While ZKH currently prints a higher short-term Unified Composite Score (50.3/100 HOLD vs. ZJYL 33.4/100 SELL), ZJYL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -0.8% operating margin) and revenue trajectory (-9.7% vs. +12.8% YoY).
  • Technical & Structure Timing Caution: ZKH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile ZJYL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZKH vs ZJYL
ZKH NYSE
ZKH Group Limited American Depositary Shares, each representing thirty-five (35) Class A Ordinary Shares
Retail-Building Materials, Hardware, Garden Supply
$1.47
+4.26% 1D
Market Cap $222.5M
TTM Revenue $9.44B
Forward P/E 3.3x
Beta / 30D Vol -0.20β · 94% Vol
Unified Composite Score
50.3 / 100 HOLD
Tech 65.0 Fund 68.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $1.47 · SMA50: $2.06
ZJYL NASDAQ Head-to-Head Winner
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$3.34
-0.6% 1D
Market Cap $534.9M
TTM Revenue $508M
Forward P/E N/M
Beta / 30D Vol 13.88β · 178% Vol
Unified Composite Score
33.4 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.0% over 20 days), RSI 55
RSI-14: 54.6 · SMA20: $3.04 · SMA50: $2.43

6-Pillar Scorecard Institutional Category Breakdown (ZKH 1 – 4 ZJYL)

Columns: Metric · ZKH · ZJYL
1. Valuation Multiples ZJYL
Forward P/E 3.3x N/M
Trailing P/E 28.2x 17.7x
PEG Ratio N/M N/M
EV / Revenue N/M 1.1x
2. Growth & Scale ZKH
Revenue Growth (YoY) +12.8% -9.7%
Earnings Growth (YoY) +0.0% -32.0%
TTM Revenue (USD) $9.44B $508M
Market Cap $222.5M $534.9M
3. Profitability & Quality ZJYL
Gross Margin 16.6% 31.3%
Operating Margin -0.8% 2.1%
Net Profit Margin -0.0% 5.9%
Return on Equity (ROE) -0.1% 4.0%
4. Balance Sheet & Cash Flow ZJYL
Cash Generation (TTM) -$34M EBITDA $17M EBITDA
Cash Flow Margin -0.4% EBITDA Mgn 3.3% EBITDA Mgn
Net Cash / Leverage $2.70 Book/Sh · -0.1% ROE $3.87 Book/Sh · 4.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ZJYL
OpEx & R&D Intensity 17.4% of Rev ($1.64B) 29.2% of Rev ($148M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Internet Retail Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZKH (4) vs ZJYL (6)
Institutional Metric ZKH ZJYL Criterion Row Edge
Market Capitalization
Scale
$222.5M $534.9M Larger Scale ZJYL
Trailing P/E Ratio
Valuation
28.2x 17.7x Lower Multiple ZJYL
Forward P/E Ratio
Valuation
3.3x N/M Lower Multiple ZKH
Revenue Growth (YoY)
Growth
+12.8% -9.7% Higher Growth ZKH
Operating Margin (TTM)
Profitability
-0.8% 2.1% Higher Margin ZJYL
Net Profit Margin
Profitability
-0.0% 5.9% Higher Margin ZJYL
Return on Equity (ROE)
Capital Efficiency
-0.1% 4.0% Higher ROE ZJYL
52-Week Range Position
Momentum
10% ($1–$4) 67% ($0–$5) Stronger Trend ZJYL
Beta / 30D Volatility
Risk Regime
-0.20β · 94% Vol 13.88β · 178% Vol Lower Realized Risk ZKH
Unified Institutional Score
Composite Signal
50.3 / 100 (HOLD) 33.4 / 100 (SELL) Higher Composite ZKH
Trailing 12M Revenue (USD)
Operating Scale
$9.44B $508M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.6% 31.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$34M EBITDA ($2.70 Book/Sh · -0.1% ROE) $17M EBITDA ($3.87 Book/Sh · 4.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZJYL +76.68 pp
ZKH: -16.95% · ZJYL: +59.73%
3M Horizon ZJYL +59.18 pp
ZKH: -49.31% · ZJYL: +9.87%
6M Horizon ZJYL +95.68 pp
ZKH: -49.83% · ZJYL: +45.85%
1Y Horizon ZJYL +1188.84 pp
ZKH: -51.8% · ZJYL: +1137.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZKH vs ZJYL. Trailing 12-month operating profitability (ZKH -0.8% vs ZJYL 2.1%) and valuation multiples (ZKH 3.3x vs ZJYL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ZKH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$9.44B
Gross Margin16.6%
Op. Margin-0.8%
ROE / Fwd P/E-0.1% · 3.3x
ZJYL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$508M
Gross Margin31.3%
Op. Margin2.1%
ROE / Fwd P/E4.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZKH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZKH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZJYL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZJYL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZKH Moat Profile Cyclical / Execution-Driven Positioning
Internet Retail Operator
Competes within the Internet Retail value chain with $222.5M market capitalization and -0.8% operating margin.
OpEx & R&D Reinvestment 17.4% of Rev ($1.64B)
90D Engineering Disclosures 0 Published
ZJYL Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $534.9M market capitalization and 2.1% operating margin.
OpEx & R&D Reinvestment 29.2% of Rev ($148M)
90D Engineering Disclosures 0 Published

Investor FAQ ZKH vs ZJYL Key Questions & Quantitative Answers

As of Nov 19, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over ZKH Group Limited (ZKH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ZKH carries a Unified Composite Score of 50.3/100 (HOLD) at $1.47 (3.3x Forward P/E, -0.8% operating margin), whereas ZJYL carries 33.4/100 (SELL) at $3.34 (N/M Forward P/E, 2.1% operating margin). Composite vs. Pillar Nuance: While ZKH currently prints a higher short-term Unified Composite Score (50.3/100 HOLD vs. ZJYL 33.4/100 SELL), ZJYL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -0.8% operating margin) and revenue trajectory (-9.7% vs. +12.8% YoY). Technical & Structure Timing Caution: ZKH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile ZJYL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZKH leads the Growth & Scale pillar: ZKH posts +12.8% YoY revenue growth and +0.0% YoY earnings growth on $9.44B TTM revenue (16.6% gross margin, -0.8% operating margin), compared with ZJYL at -9.7% YoY revenue growth and -32.0% YoY earnings growth on $508M TTM revenue (31.3% gross margin, 2.1% operating margin). On trailing 12-month operating scale, ZKH generates $9.44B in USD-normalized revenue versus $508M for ZJYL. In operating R&D and SG&A reinvestment, ZKH deploys 17.4% of Rev ($1.64B) (0 90-day corporate R&D disclosures) versus 29.2% of Rev ($148M) (0 disclosures) for ZJYL.

ZJYL screens cheaper on headline valuation multiples. ZKH trades at 3.3x Forward P/E, 28.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (-0.4% EBITDA margin), whereas ZJYL trades at N/M Forward P/E, 17.7x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (3.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZKH (-0.1% ROE) versus ZJYL (4.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ZKH carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.20β · 94% Vol realized risk). By comparison, ZJYL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (13.88β · 178% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

ZKH Group Limited American Depositary Shares, each representing thirty-five (35) Class A Ordinary Shares (ZKH) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.